Drug Details
General Information of the Drug (ID: DR0490) | ||||
---|---|---|---|---|
Name |
Etoposide
|
|||
Synonyms |
etoposide; 33419-42-0; VePesid; Toposar; trans-Etoposide; Lastet; (-)-Etoposide; Zuyeyidal; Etoposido; Etoposidum; Etoposidum [INN-Latin]; VP-16; Etoposide (VP16); VP 16-213; VP 16 (pharmaceutical); Vepesid J; Etoposido [INN-Spanish]; Etopophos (phosphate salt); VP 16; VP-16-213; VP 16213; UNII-6PLQ3CP4P3; NK 171; NSC-141540; NSC 141540; CCRIS 2392; HSDB 6517; EINECS 251-509-1; Epipodophyllotoxin VP-162
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Testicular carcinoma [ICD-11: 2C80] | Approved | [1] | |
Structure |
![]() |
Click to Download Mol2D MOL |
||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
C29H32O13
|
|||
PubChem CID | ||||
Canonical SMILES |
CC1OCC2C(O1)C(C(C(O2)OC3C4COC(=O)C4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O
|
|||
InChI |
1S/C29H32O13/c1-11-36-9-20-27(40-11)24(31)25(32)29(41-20)42-26-14-7-17-16(38-10-39-17)6-13(14)21(22-15(26)8-37-28(22)33)12-4-18(34-2)23(30)19(5-12)35-3/h4-7,11,15,20-22,24-27,29-32H,8-10H2,1-3H3/t11-,15+,20-,21-,22+,24-,25-,26-,27-,29+/m1/s1
|
|||
InChIKey |
VJJPUSNTGOMMGY-MRVIYFEKSA-N
|
|||
CAS Number |
CAS 33419-42-0
|
|||
GDSC | ||||
TTD Drug ID | ||||
DrugBank ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Arsenic trioxide | Realgar and orpiment | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | A-673 | CVCL_0080 | Ewing sarcoma | Homo sapiens | ||
RD-ES | CVCL_2169 | Ewing sarcoma | Homo sapiens | |||
SK-N-MC | CVCL_0530 | Ewing sarcoma | Homo sapiens | |||
mesenchymal stem cell | Healthy | Homo sapiens | ||||
Experimental
Result(s) |
Arsenic trioxide potentiates the effectiveness of etoposide in Ewing sarcomas. | |||||
Curcumin | Hellenia speciosa | Click to Show/Hide the Molecular Data of This NP | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Biological
Regulation |
Up-regulation | ROS generation | ||||
In-vitro Model | HL-60 | CVCL_0002 | Adult acute myeloid leukemia | Homo sapiens | ||
In-vivo Model | 1*106 BNML cells in 0.5 mL of PBS injected into tail vein in male Brown Norway (BN/CrlCmd) rats. | |||||
Experimental
Result(s) |
Curcumin can increase the antileukemic effect of etoposide through reactive oxygen species in sensitive myeloid leukemia cells, and it is harmless to normal human cells. | |||||
Elemene | Pogostemon cablin | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [4] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | TP53 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
Experimental
Result(s) |
Synergistic antitumor effect of Beta-elemene and etoposide is mediated via induction of cell apoptosis and cell cycle arrest in non-small cell lung carcinoma cells. | |||||
Fisetin | Toxicodendron succedaneum | Click to Show/Hide the Molecular Data of This NP | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [5] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Down-regulation | Expression | CCNB1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | CCNE1 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | MG-63 | CVCL_0426 | Osteosarcoma | Homo sapiens | ||
SaOS-2 | CVCL_0548 | Osteosarcoma | Homo sapiens | |||
U2OS | CVCL_0042 | Osteosarcoma | Homo sapiens | |||
Experimental
Result(s) |
The combination of fisetin with etoposide has higher anti-proliferative effects in osteosarcoma associated with cell cycle arrest, allowing the use of lower doses of the chemotherapeutic agent. | |||||
Hesperetin | Citrus limon | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [6] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Biological
Regulation |
Induction | Cell cycle arrest in G2 phase | ||||
In-vitro Model | U2OS | CVCL_0042 | Osteosarcoma | Homo sapiens | ||
Experimental
Result(s) |
Hesperetin combined with etoposide showed additive effects on the inhibition of cell growth. | |||||
Resveratrol | Gnetum parvifolium | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [7] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Up-regulation | Expression | TP53 | Molecule Info |
Pathway MAP
|
|
In-vitro Model | HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | ||
Experimental
Result(s) |
Combination of resveratrol and etoposide showed synergistic anti-proliferative effect on hepatocellular carcinoma cells. |









